Unlike conventionalFGS agents, inclusion of the MMC enabled quantitative comparison to 68Ga-DOTA-TOC as a benchmark and showed that dye conjugationdid not impair SSTR2 binding in cells and animal models.16,17 Furthermore, ex vivo staining of pancreatic NET(pNET) biospecimens showed high specificity for human SSTR2-expressingtumors and correlated with gold standard histopathology, demonstratingfor the first time that a clinical radiotracer could be adapted forFGS. The gene discussed is SSTR2; the disease is pancreatic neuroendocrine tumor.